May 22, 2022 new design drugs at low prices: psychostimulators, opiates, Psychedelics, Dissociatives, Cannabinoids and New Chemicals new chemical research, you can find new legal stimulants, new legal opiates, new legal dissociatives, legal psychedelics, legal marijuana.





AD-1211 is an opioid with excellent analgesic properties and atypical opioid effects. AD-1211 was first synthesized in the 1970s by the Dainippon Pharmaceutical Company for pharmacological purposes. Structurally it is a 1-substituted-4-prenyl-piperazine derivative and structurally AD-1211 is not related to any other opioids. The S-enantiomers of the isomers of this substance, are more active than the R-enantiomers and are mixed agonist-antagonist opioid receptors.

The effects of AD-1211 are similar to those of pentazocine. Studies in rodents have shown that this drug can be addictive or tolerant if administered regularly.

You can buy AD-1211 online right now from our manager as a designer drug for chemical research.

  • AD-1211
IUPAC    1-(3-Methyl-2-butenyl)-4-[(1R)-1-phenyl-2-(3-hydroxyphenyl)ethyl]piperazine
Formula    C23H30N2O
Molecular weight    350.506 g·mol−1
CAS    83374-58-7
Appearance    Powder
Purity    ≥ 98 %

AD-1211 and all other drugs sold on this website are intended for research and legal applications. AD-1211 is a designer drug with obvious physiological and psychoactive effects.

Side effects from AD-1211 are not known.

Storage conditions: in a cool and dry place. Terms AD-1211 , can last up to 2 years with proper storage conditions.


We would like to draw your attention to the fact that before you place an order on our website, we checked the legality of the necessary chemicals. The list of permitted chemicals you should know in your country. We did not send orders to Russia, Belarus, Hong Kong, Singapore. We would like you not to order prohibited chemicals in your country.

By purchasing chemical studies on you buy a chemical at a wholesale price and get a discount coupon on subsequent purchases on our website.  

You may have missed